Article (Scientific journals)
L'etude Proactive: prevention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabetique de type 2.
Scheen, André; Lefebvre, Pierre
2005In Revue Médicale de Liège, 60 (11), p. 896-901
Peer reviewed
 

Files


Full Text
200511_14.pdf
Publisher postprint (441 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Administration, Oral; Cardiovascular Diseases/etiology/prevention & control; Diabetes Mellitus, Type 2/complications/drug therapy; Humans; Hypoglycemic Agents/administration & dosage/therapeutic use; Insulin/therapeutic use; Placebos; Risk Factors; Thiazolidinediones/administration & dosage/therapeutic use
Abstract :
[en] PROactive is a prospective, randomised controlled trial in 5238 patients with type 2 diabetes who had evidence of macrovascular disease. Patients were assigned to oral pioglitazone titrated from 15 mg to 45 mg or matching placebo, to be taken in addition to their glucose-lowering drugs and other medications. After a mean follow up of 34.5 months, pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke (intention to treat analysis: hazard ratio = 0.84; 95% CI: 0.72-0.98; p = 0.027). Various favourable metabolic effects could contribute to this cardiovascular protection, i.e. an absolute 0.5 % reduction in HbA1c, a 9% increase in HDL cholesterol, a 13% decline of triglycerides, and a 3 mm Hg reduction in systolic blood pressure in the pioglitazone group compared to placebo. The requirement of insulin was reduced by almost 50% in the pioglitazone group as compared to the placebo group. The incidence of cases of oedema and congestive heart failure was higher in the pioglitazone group. In conclusion, in patients with type 2 diabetes who are at high cardiovascular risk, pioglitazone improves cardiovascular outcome, and reduces the need to add insulin to glucose-lowering regimens compared to placebo.
Disciplines :
Cardiovascular & respiratory systems
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Lefebvre, Pierre ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
French
Title :
L'etude Proactive: prevention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabetique de type 2.
Alternative titles :
[en] Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients
Publication date :
2005
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
60
Issue :
11
Pages :
896-901
Peer reviewed :
Peer reviewed
Additional URL :
Available on ORBi :
since 26 March 2009

Statistics


Number of views
1236 (10 by ULiège)
Number of downloads
694 (1 by ULiège)

Scopus citations®
 
15
Scopus citations®
without self-citations
6

Bibliography


Similar publications



Contact ORBi